Effects of brucine combined with glycyrrhetinic acid or liquiritin on rat hepatic cytochrome P450 activities in vivo

Yaoxue Xuebao

Volumn 46, Issue 5, 2011, Pages 573-580

  Xing, Pan Pan ^a   Wu, Wen Hua ^a   Du, Peng ^a   Han, Feng Mei ^a   Chen, Yong ^a  

^a HUBEI UNIVERSITY   (China)

Author keywords

Brucine; Co administration; CYP450; Glycyrrhetinic acid; Liquiritin

Indexed keywords

4 NITROPHENOL; BRUCINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; ETHOXYRESORUFIN DEETHYLASE; GLYCYRRHETINIC ACID; LIQUIRITIN; MESSENGER RNA; TESTOSTERONE; TOLBUTAMIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HYDROXYLATION; IN VIVO STUDY; LIVER; NONHUMAN; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FLAVANONES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSIDES; GLYCYRRHETINIC ACID; HYDROXYLATION; LIVER; MALE; NITROPHENOLS; PLANTS, MEDICINAL; RATS; RATS, WISTAR; RNA, MESSENGER; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; STRYCHNINE; STRYCHNOS NUX-VOMICA; TOLBUTAMIDE;

EID: 79960724605     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Deng XK, Yin W, Li WD, et al. The anti-tumor effects of alkaloids from the seeds of Strychnos nux-vomica on HepG2 cells and its possible mechanism [J]. J Ethnopharmacol, 2006, 106: 179-186. (Pubitemid 43766195)
2. Wang YH, Qiao B, Jiang JL, et al. Fingerprints of Strychnos nux-vomica L. study by HPLC [J]. J Chin Tradit Herb Drug, 2006, 37: 1252-1255.
3. Rao PS, Ramanadham M, Prasad MNV. Anti-proliferative and cytotoxic effects of Strychnos nux-vomica root extract on human multiple myeloma cell line-RPMI 8226 [J]. Food Chem Toxicol, 2009, 47: 283-288.
4. Li L. The overview of efficacy and attenuated of Strychnos nux-vomica study [J]. Asia-Pacific Tradit Med, 2007, 5: 19-21.
5. Mori H, Niwa K, Zheng Q, et al. Cell proliferation in cancer prevention: effects of preventive agents on estrogen-related endometrial carcinogenesis model and on an in vitro model in human colorectal cells [J]. Mutat Res, 2001, 480/481: 201-207.
6. Kamei J, Nakamura R, Ichiki H, et al. Antitussive principles of glycyrrhizae radix, a main component of the Kampo preparations Bakumondo-to (Mai-men-dong-tang) [J]. Eur J Pharmacol, 2003, 469: 159-163. (Pubitemid 36629562)
7. Kim YW, Ki SH, Lee JR, et al. Liquiritigenin, an aglycone of liquiritin in glycyrrhizae radix, prevents acute liver injuries in rats induced by acetaminophen with or without buthionine sulfoximine [J]. Chem Biol Interact, 2006, 161: 125-138. (Pubitemid 43776630)
8. Estabrook RW. A passion for P450s (rememberances of the early history of research on cytochrome P450) [J]. Drug Metab Dispos, 2003, 31: 1461-1473. (Pubitemid 37466915)
9. Zhu LQ, Lou JS. Resent studies on cytochrome P450 and drug metabolism [J]. Chin J Clin Pharmacol Ther, 2004, 9: 1081-1086.
10. Oinonen T, Lindros KO. Zonation of hepatic cytochrome P-450 expression and regulation [J]. Biochem J, 1998, 329: 17-35. (Pubitemid 28022286)
11. Ronis MJ, Lindros KO, Sundberg MI. In cytochromes P450: metabolic and toxicological aspects [C]. Boca Raton, FL: CRC Press, 1996: 211-239.
12. Shapiro BH, Pampori NA, Ram PA, et al. Irreversible suppression of growth hormone-dependent cytochrome P-450 2C11 in adult rats neonatally treated with monosodium glutamate [J]. J Pharmacol Exp Ther, 1993, 265: 979-984. (Pubitemid 23315613)
13. Deng XK, Yin W, Cai BC, et al. Anti-tumor activity and toxicity of brucine on mice with transplanted Heps [J]. Chin Pharmacol Bull, 2006, 22: 35-39.
14. Yin W, Wang TS, Yin FZ, et al. Analgesic and antiinflammatory properties of brucine and brucine N-oxide extracted from seeds of Strychnox nux-vomica [J]. J Ethnopharmacol, 2003, 88: 205-214. (Pubitemid 37083448)
15. Philippe G, Angenot L, Tits M, et al. About the toxicity of some Strychnos species and their alkaloids [J]. Toxicon, 2004, 44: 405-416. (Pubitemid 39070641)
16. Naik BS, Chakrapani M. A rare case of brucine poisoning complicated by rhabdomyolysis and acute renal failure [J]. Malays J Pathol, 2009, 31: 67-69.
17. Li XT, Chen XJ, Wang GJ. Study on pharmacokinetics of brucine in mice [J]. Chin Pharm J, 2004, 39: 452-454.
18. Yamada H, Minematsu Y, Nakamura T, et al. Brucine as a potent inducer of CYP2B3, the third member of the CYP2B subfamily P450 in rats [J]. Biol Pharm Bull, 1996, 19: 291-293. (Pubitemid 26088362)
19. Fujisaki H, Mise M, Ishii Y, et al. Strychnine and brucine as the potent inducers of drug metabolizing enzymes in rat liver: different profiles from phenobarbital on the induction of cytochrome P450 and UDP- glucuronosyltransferase [J]. J Pharmacol Exp Ther, 1994, 268: 1024-1031. (Pubitemid 24085910)
20. Peng ZH, Song W, Han FM, et al. In vitro and in vivo study of papaverine and its major metabolites [J]. Acta Pharm Sin, 2009, 44: 95-100.
21. Hoen PAC, Bijsterbosch MK, Berkel TJC, et al. Idazolam is a phenobarbital-like cytochrome P450 inducer in rats [J]. J Pharmacol Exp Ther, 2001, 299: 921-927. (Pubitemid 33104960)
22. Sarich TC, Adams SP, Petricca G, et al. Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor [J]. J Pharmacol Exp Ther, 1999, 289: 695-702. (Pubitemid 29191221)
23. Kim SG, Williams D, Schuetz E, et al. Pyridine induction of cytochrome P-450 in the rat: role of P-450 (alcohol inducible form) in pyridine N-oxidation [J]. J Pharmacol Exp Ther, 1988, 246: 1175-1181.
24. Relling MV, Aoyama T, Gonzalez FT, et al. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily [J]. J Pharmacol Exp Ther, 1990, 252: 442-447. (Pubitemid 20067748)
25. Zhang MF, Zhang J. Pharmacokinetics research on glycyrrhizin [J]. Clin Medicat J, 2009, 7: 44-49.
26. Zhao ZY, Wang WX, Guo HZ, et al. The effect of liquiritin on body weight and behavior of depressive rats [J]. Chin Ment Health J, 2006, 20: 787-790.
27. Gonzalez FJ. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1 [J]. Mutat Res, 2005, 569: 101-110. (Pubitemid 39643260)
28. Arzu G, Marja LD. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms [J]. Pharmacogenomics, 2008, 9: 635-637.
29. Yao HT, Lin PP, Chang YW, et al. Effect of taurine supplementation on cytochrome P450 2E1 and oxidative stress in the liver and kidneys of rats with streptozotocin-induced diabetes [J]. Food Chem Toxicol, 2009, 47: 1703-1709.
30. Matsubara T, Kim HJ, Miyata M, et al. Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat [J]. J Pharmacol Exp Ther, 2004, 309: 1282-1290. (Pubitemid 38669720)
31. Quattrochi LC, Guzelian PS. CYP3A regulation: from pharmacology to nuclear receptors [J]. Drug Metab Dispos, 2001, 29: 615-622. (Pubitemid 32374560)